Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer (Increase)

Inclusion Criteria:

1. Voluntarily sign the informed consent form;
2. 18-75 years old;
3. The expected survival period is ≥12 weeks;
4. Eastern Cooperative Oncology Group (ECOG) score [0-2] points;
5. The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as >1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification);
6. Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure;
7. In the state of disease progression before enrollment;
8. Measurable disease according to RECIST version 1.1 or only bone metastasis;
9. Adequate hematological, hepatic and renal function;
10. NYHA class I or II and Left ventricular ejection fraction (LVEF) ≥50%.
11. The diagnosis of invasive carcinoma by histology or cytology: Hormone receptor (HR) positive (defined as >1% nuclear estrogen receptor staining); HER2 positive (defined as IHC 3+, or HER2 FISH detection amplification);
12. In the state of disease progression before enrollment;
13. Have lesions able to and agree to perform tissue biopsy at the time requested in the study;
14. Treatment ≥1 line after recurrence/metastasis, or relapse within 12 months after completing trastuzumab-based adjuvant therapy or during trastuzumab adjuvant therapy;
15. Previously received trastuzumab for anti-HER2 therapy;
16. Measurable disease according to RECIST version 1.1.

Exclusion Criteria:

1. Allergic to the ingredients of Inetetamab, cyclophosphamide or similar drugs;
2. Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study;
3. Patients who cannot accept drugs orally;
4. Women who are pregnant or breastfeeding or planning to give birth;
5. Patients with currently symptomatic brain or meningeal metastasis;
6. History of other primary malignancy;
7. Resistant to steroidal or nonsteroidal aromatase Inhibitor;
8. Have used Inetetamab;
9. Patients with life-threatening, symptomatic, metastatic visceral disease.